漢康-KY創 News Releases

HanchorBio Announces Receipt of U.S. FDA Type C Meeting Minutes Supporting HCB101 Development Path in Second-Line Gastric/GEJ Cancer

HanchorBio Inc. has received the official minutes from a Type C meeting with the U.S. FDA regarding … · 2026-06-30

HanKang-KY Chuang Announces Board Resolution to Issue Restricted Employee Stock Rights

HanKang-KY Chuang's board has resolved to issue 1,501,036 restricted shares to employees at prices r… · 2026-06-18

Han Kang-KY Chuang Announces Board Resolution to Issue Employee Stock Options Below Market Price

Han Kang-KY Chuang's board has resolved to issue employee stock options below market price to incent… · 2026-06-18

Hankang-KY Chuang Announces Board Resolution to Convene 2026 First Extraordinary Shareholders' Meeting

Hankang-KY Chuang has announced the convening of its 2026 First Extraordinary Shareholders' Meeting … · 2026-06-18

Hankang-KY Announces Resignation of Director

Hankang-KY announced that its director, He Dong-guang, resigned effective June 17, 2026, due to pers… · 2026-06-17

[Hankang-KY] May 2026 Revenue at NT$0.00 Billion (YoY Change N/A)

Hankang-KY (Code: 7827), a company in the biotechnology and medical industry, announced its monthly … · 2026-05-01